



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|---------------------|------------------|
| 10/022,710 | 12/13/2001 | Carl Johan Friddle | LEX-0290-USA | 2137 |
| 7590 | 03/03/2004 | | EXAMINER | |
| Lance K. Ishimoto Lexicon Genetics Incorporated 4000 Research Forest Drive The Woodlands, TX 77381 | | | SCHNIZER, HOLLY G | |
| | | | ART UNIT | PAPER NUMBER |
| | | | 1653 | |

DATE MAILED: 03/03/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/022,710

Applicant(s)

FRIDDLE ET AL.

Examiner

Holly Schnizer

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 29 March 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date 5-28-02.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

Status of the Claims

Claims 1-3 are pending and have been considered in this Office Action.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-3 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility. Since a specific and substantial utility has not been found, credibility has not been assessed.

The Specification asserts that the polynucleotides of the invention have specific utilities including methods of treatment, diagnosis, screening for drugs, methods of making transgenic animals, methods of making the protein of the invention, as a chromosome marker, DNA markers for restriction fragment length polymorphisms and in forensic biology, in microarrays to identify and characterize temporal and tissue specific expression, and methods of screening libraries.

The asserted utilities that the claimed polynucleotides could be used in methods of treatment, diagnosis, screening for drugs, or as a DNA marker do not appear to be specific or substantial. These asserted utilities are not considered specific because they are merely a general statement of diagnosis or treatment of unspecified diseases and are not specific to the claimed polynucleotides. For example, any nucleic acid

Art Unit: 1653

molecule could be used to screen for some sort of pharmaceutical agent (drug). These asserted utilities are not considered substantial because they require carrying out further research to identify a disease the polynucleotide could be used to treat. A “substantial utility” is a utility that defines a “real world” use. Utilities that require or constitute carrying out further research to identify or reasonably confirm a “real world” context of use are not substantial utilities (see Examiner’s Training Materials for the Utility Guidelines at [www. USPTO.gov](http://www.USPTO.gov) at p. 6 for a list of examples of situations that do not define “substantial utilities”). In the present case, neither the Specification nor the art of record disclose any diseases or conditions related to the proteins encoded by the polynucleotides of the invention. Thus, the asserted utility of a method of treatment diagnosis, or screening for drugs for an unspecified, undisclosed disease or condition does not define a “real world context of use. Treating or diagnosing an unspecified, undisclosed disease or condition or screening for drugs to treat it would require or constitute carrying out further research to identify or reasonable confirm a “real world” context of use.

The asserted utilities of making transgenic animals and assays to identify compounds are not considered specific because the Specification has not indicated how the asserted utility is specific for the claimed polynucleotides. For example, any polynucleotide molecule could be used to identify some sort of compound.

The asserted utilities of making transgenic animals, assays to identify compounds, and methods of making the protein are not considered substantial because they amount to methods of making a material that itself has no specific and substantial

Art Unit: 1653

utility. As indicated above, the present Specification implies that the polynucleotides of the invention are structurally similar to polynucleotides encoding various protein functions (e.g. cell adhesion proteins, semaphorins, and a variety of cell surface markers and receptors; see p. 2 1st paragraph). The art shows that closely related polynucleotides encode proteins that belong to a Thrombospondin type I Repeat superfamily but the art indicates that the proteins of this superfamily have diverse functions. For example, the semaphorin family (which belongs to the Thrombospondin repeat superfamily) contains proteins that are secreted, some that are associated with the cell surface, and others that are transmembrane proteins and a wide variety of functions. Moreover, a sequence search did not reveal any sequences identical or related to the sequences of the present invention of the present invention that were known at the time of the invention. Therefore, at the time of the invention the art did not teach or suggest that the proteins encoded by the polynucleotides with similar sequences to those of the present invention were related to any disease or disorder. It appears that the function of the proteins encoded by the polynucleotides of the invention are unknown and the relationship of the proteins encoded by the claimed polynucleotides to any disease or disorder is unknown. The asserted utilities of making transgenic animals, assays to identify compounds, and making the protein are also not considered substantial because the activity specific to the proteins of the invention appears to be unknown. Therefore, such asserted utilities amount to basic research to characterize the encoded protein itself, methods of identifying materials that have no

Art Unit: 1653

specific and/or substantial utilities and method of making materials (the protein of the invention) that do not have specific and/or substantial utilities.

The assertion that the polynucleotides of the invention could be used as a chromosome marker is also not considered a specific utility in the absence of a disclosure of a specific DNA target. A "specific utility" is a utility that is specific to the subject matter claimed. In the present case, the specification indicates that it appears that proteins of the present invention are encoded by a gene that is on chromosome 2. However, the Specification is no more specific than citing chromosome 2 as an "apparent" location of a gene related to the DNA of the invention. Such is a general statement and does not include specifics such as where on chromosome 2 one would want to look or why one would want to look at it.

The assertion that the polynucleotides of the invention could be used as a DNA marker in forensic biology is not considered a substantial utility because there is no evidence that the claimed polynucleotides have sequences that vary from person to person that would allow such an identification. Thus, further research would be required to reasonably confirm or identify how the polynucleotides could be used in such assays.

The assertion that the claimed polynucleotides could be used in microarrays to identify and characterize tissue specific expression is not considered a substantial utility because it amounts to basic research for studying the properties of the claimed product itself (see Utility Guidelines Training Materials available at www.USPTO.gov, p. 6).

In addition, the assertion that the claimed polynucleotides could be used to screen libraries or in methods of making the protein are not considered a substantial

Art Unit: 1653

utilities because, as explained above, the Specification does not provide any asserted utility for the claimed polynucleotides or those close in sequence that would be found in such a screening assay. Likewise, the Specification does not provide any guidance as to the function of the encoded protein or any diseases or disorders it is related to. Thus, the asserted utility amounts to a method of assaying or identifying a material that itself has no specific or substantial utility (see Utility Guidelines Training materials available at [www. USPTO.gov](http://www.USPTO.gov), p. 6).

Claims 1-3 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-3 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Art Unit: 1653

Even in the case that the claimed polynucleotides were shown to be supported by a specific and substantial utility, the Specification does not provide support for using the claimed polynucleotides in any methods of treatment or diagnosis or methods of screening for drugs. Factors to be considered in determining whether undue experimentation is required, are summarized in *In re Wands* (858 F2d, 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988)). These factors include (1) quantity of experimentation, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims.

The nature of the invention involves the discovery of polynucleotides encoding proteins that "share structural similarity with mammalian membrane proteins, such as cell adhesion proteins, as well as semaphorins, and a variety of cell surface markers and receptors. The Specification discloses three related polynucleotide sequences and their encoded protein sequences. The polynucleotide of SEQ ID NO: 5 is the longest sequence containing 4821 nucleotides. SEQ ID NO:3 contains 4773 nucleotides that are identical in sequence to nucleotides 49-4821 of SEQ ID NO:5. SEQ ID NO:1 contains 4398 nucleotides that are identical in sequence to nucleotides 424-4821 of SEQ ID NO:3. The polynucleotide sequence of SEQ ID NO:1 and the encoded protein of SEQ ID NO:2 are highly similar to polynucleotides encoding a protein of unidentified function (see sequence alignment attached). The Specification does not specifically disclose the activity of the proteins of the invention but indicates that they are

structurally similar to cell adhesion proteins, as well as semaphorins, and a variety of cell surface markers and receptors (p. 2, 1st paragraph). Thus, it appears that the protein functions encoded by the polynucleotides of the present invention were unknown and using the claimed polynucleotides would require characterization of the role and relationship of the encoded protein to any diseases or disorders in order to use the claimed polynucleotides any method of treating or diagnosing a disease or screening for drugs.

The Specification only provides general guidance as to how polynucleotides may be used in such methods as treatments, diagnosis, protein production, transgenic animal production, library screening, DNA marker, but does not provide any specific information regarding how the proteins of the present invention would be used in such assays. For example, what diseases could be treated or diagnosed with the claimed polynucleotides? How is the polynucleotide related to disease in terms of diagnosis? Would one look for increases or decreases in mRNA, and/or modifications in the polynucleotide sequence and if so, what types of modifications (mutations, deletions, insertions)? In addition, the Specification does not teach what effects the deletions contained in SEQ ID NOs: 1, 3, or 5 would have on the function of the encoded protein.

There are no working examples of using the claimed polynucleotides.

In a sequence search, sequences identical to SEQ ID NOs: 1, 3, and 5 were not found. Thus, it appears that the state of the prior art is such that proteins of the invention and polynucleotides encoding them were unknown. The prior art does disclose a closely related sequence but does not provide any guidance as to the identity

Art Unit: 1653

or function of the encoded protein (see sequence alignment attached to this Office Action).

The relative skill of those in the prior art is such that the proteins of the invention could be expressed using the claimed polynucleotides and the function of the proteins could be elucidated with further research. However, given the guidance provided in the Specification and in the prior art, the skilled artisan would not be able to predict with any expectation of success, the relationship of the claimed polynucleotide or the protein it encodes with any disease. Thus, the art of using a cDNA encoding a protein with unknown function to treat an undefined disease is highly unpredictable.

A large quantity of experimentation would be required to determine the physiological role of the protein encoded by the claimed polynucleotide, to determine what parts of the sequence can be deleted and to determine the relationship of the polynucleotide to a disease in order to use it in any methods of treatment or diagnosis. To use the claimed polynucleotides would not require just a repetition of the work that is described in the instant application but a substantial inventive contribution on the part of a practitioner which would involve the characterization of the physiological role of the encoded protein and its relationship, if any, to a disease or disorder. It is this additional characterization of the polynucleotide and encoded protein that constitutes undue experimentation.


Conclusions

No Claims are allowable.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Holly Schnizer whose telephone number is (571) 272-0958. The examiner can normally be reached on Tuesdays, Thursdays, and Fridays from 8 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571) 272-0951. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.


Holly Schnizer
February 27, 2004


CHRISTOPHER S. F. LOW
SUPERVISORY PATENT EXAM-
TECHNOLOGY CENTER 180